Skip to main content
SpringerLink
Log in

Reducing the Risk of and Screening for Pancreatic Cancer

  • Living reference work entry
  • First Online:
Hepato-Pancreato-Biliary Malignancies

  • 44 Accesses

Abstract

Pancreatic cancer has a high morbidity and mortality with 5-year survival rate below 5%. One of the major causes of this dismal survival rate is lack of tumor detection at an early stage. Identifying high-risk population can help in developing screening programs, thereby helping early diagnosis of neoplastic changes and impacting patient outcomes by allowing timely detection and intervention of pancreatic neoplasms. This chapter highlights the high-risk population for pancreatic cancer screening, modalities of screening, the risks and benefits of screening, and the endpoint of screening programs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Cancer, N.C.I.C.s.f.p. https://seer.cancer.gov/statfacts/html/pancreas

  2. Hruban RH, et al. Update on familial pancreatic cancer. Adv Surg. 2010;44:293–311.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kamisawa T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85.

    Article  CAS  PubMed  Google Scholar 

  4. Canto MI, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47.

    Article  PubMed  Google Scholar 

  5. Goggins M, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7–17.

    Article  CAS  PubMed  Google Scholar 

  6. Syngal S, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62. quiz 263.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020;159(1):358–62.

    Article  CAS  PubMed  Google Scholar 

  8. Shi C, et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res. 2009;15(24):7737–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Potjer TP, et al. Variation in precursor lesions of pancreatic cancer among high-risk groups. Clin Cancer Res. 2013;19(2):442–9.

    Article  PubMed  Google Scholar 

  10. Sohn TA, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239(6):788–97. discussion 797–9.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sawai Y, et al. Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms. Endoscopy. 2010;42(12):1077–84.

    Article  CAS  PubMed  Google Scholar 

  12. Uehara H, et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut. 2008;57(11):1561–5.

    Article  CAS  PubMed  Google Scholar 

  13. Canto MI, et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology. 2018;155(3):740–751. e2.

    Article  PubMed  Google Scholar 

  14. Yu J, et al. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut. 2017;66(9):1677–87.

    Article  CAS  PubMed  Google Scholar 

  15. Meckler KA, et al. Familial fibrocystic pancreatic atrophy with endocrine cell hyperplasia and pancreatic carcinoma. Am J Surg Pathol. 2001;25(8):1047–53.

    Article  CAS  PubMed  Google Scholar 

  16. Corral JE, et al. Diagnostic yield from screening asymptomatic individuals at high risk for pancreatic cancer: a meta-analysis of cohort studies. Clin Gastroenterol Hepatol. 2019;17(1):41–53.

    Article  PubMed  Google Scholar 

  17. Paiella S, et al. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: a systematic review and proportion meta-analysis of screening results. Pancreatology. 2018;18(4):420–8.

    Article  PubMed  Google Scholar 

  18. Henrikson NB, et al. Screening for pancreatic cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2019;322(5):445–54.

    Article  PubMed  Google Scholar 

  19. Corral JE, et al. Cost-effectiveness of pancreatic cancer surveillance in high-risk individuals: an economic analysis. Pancreas. 2019;48(4):526–36.

    Article  PubMed  Google Scholar 

  20. Lowenfels AB, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89(6):442–6.

    Article  CAS  PubMed  Google Scholar 

  21. Gruber SB, et al. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res. 1998;58(23):5267–70.

    CAS  PubMed  Google Scholar 

  22. Giardiello FM, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119(6):1447–53.

    Article  CAS  PubMed  Google Scholar 

  23. van Lier MG, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105(6):1258–64. author reply 1265.

    Article  PubMed  Google Scholar 

  24. Hartge P, et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999;64(4):963–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. van Asperen CJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42(9):711–9.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Yang X, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020;38(7):674–85.

    Article  CAS  PubMed  Google Scholar 

  27. Lynch HT, et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer. 2002;94(1):84–96.

    Article  CAS  PubMed  Google Scholar 

  28. Lynch HT, et al. Pancreatic cancer and the FAMMM syndrome. Familial Cancer. 2008;7(1):103–12.

    Article  CAS  PubMed  Google Scholar 

  29. Vasen HF, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87(6):809–11.

    Article  CAS  PubMed  Google Scholar 

  30. de Snoo FA, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 2008;14(21):7151–7.

    Article  PubMed  Google Scholar 

  31. Win AK, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30(9):958–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Geary J, et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Familial Cancer. 2008;7(2):163–72.

    Article  CAS  PubMed  Google Scholar 

  33. Kastrinos F, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302(16):1790–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Swift M, et al. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991;325(26):1831–6.

    Article  CAS  PubMed  Google Scholar 

  35. Roberts NJ, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41–6.

    Article  CAS  PubMed  Google Scholar 

  36. Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology. 2010;139(4):1076–80, 1080.e1–2

    Article  PubMed  Google Scholar 

  37. Klein AP, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64(7):2634–8.

    Article  CAS  PubMed  Google Scholar 

  38. Wang W, et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol. 2007;25(11):1417–22.

    Article  PubMed  Google Scholar 

  39. Chaffee KG, et al. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med. 2018;20(1):119–27.

    Article  CAS  PubMed  Google Scholar 

  40. Wood LD, Yurgelun MB, Goggins MG. Genetics of familial and sporadic pancreatic cancer. Gastroenterology. 2019;156(7):2041–55.

    Article  CAS  PubMed  Google Scholar 

  41. Hu C, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Canto MI, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4):796–804; quiz e14–5.

    Article  PubMed  Google Scholar 

  43. Ludwig E, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011;106(5):946–54.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Harinck F, et al. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut. 2016;65(9):1505–13.

    Article  CAS  PubMed  Google Scholar 

  45. Topazian M, et al. Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc. 2007;66(1):62–7.

    Article  PubMed  Google Scholar 

  46. Brugge WR, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126(5):1330–6.

    Article  PubMed  Google Scholar 

  47. Chari ST, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504–11.

    Article  PubMed  Google Scholar 

  48. Chari ST, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95–101.

    Article  CAS  PubMed  Google Scholar 

  49. Sharma A, et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes. Gastroenterology. 2018;155(3):730–739.e3.

    Article  PubMed  Google Scholar 

  50. (v1.2020), N.C.C.N.N.g.

    Google Scholar 

  51. Stoffel EM, et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37(2):153–64.

    Article  PubMed  Google Scholar 

  52. Shelton C, Solomon S, LaRusch J, Whitcomb DC. PRSS1-related hereditary pancreatitis. 2012 Mar 1 [updated 2019 Apr 25]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021.

    Google Scholar 

  53. Abe T, et al. Deleterious germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance. J Clin Oncol. 2019;37(13):1070–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148(4):824–48. e22

    Article  PubMed  Google Scholar 

  55. Zerboni G, et al. Systematic review and meta-analysis: prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. Pancreatology. 2019;19(1):2–9.

    Article  PubMed  Google Scholar 

  56. Tanaka M, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.

    Article  PubMed  Google Scholar 

  57. Crippa S, et al. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. Gut. 2017;66(3):495–506.

    Article  PubMed  Google Scholar 

  58. Matthaei H, et al. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Ann Surg Oncol. 2011;18(12):3493–9.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Brune K, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30(9):1067–76.

    PubMed  PubMed Central  Google Scholar 

  60. Canto MI, et al. Surgical outcomes after pancreatic resection of screening-detected lesions in individuals at high risk for developing pancreatic cancer. J Gastrointest Surg. 2020;24(5):1101–10.

    Article  PubMed  Google Scholar 

  61. Rulyak SJ, et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003;124(5):1292–9.

    Article  PubMed  Google Scholar 

  62. Li D, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301(24):2553–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Gapstur SM, et al. Association of alcohol intake with pancreatic cancer mortality in never smokers. Arch Intern Med. 2011;171(5):444–51.

    Article  PubMed  Google Scholar 

  64. Ansary-Moghaddam A, et al. The effect of modifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Cancer Epidemiol Biomark Prev. 2006;15(12):2435–40.

    Article  Google Scholar 

  65. Sah RP, et al. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10(7):423–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Huxley R, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Swanson RS, et al. The 90-day mortality after pancreatectomy for cancer is double the 30-day mortality: more than 20,000 resections from the national cancer data base. Ann Surg Oncol. 2014;21(13):4059–67.

    Article  PubMed  Google Scholar 

  68. Liu J, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer. 2012;131(3):683–91.

    Article  CAS  PubMed  Google Scholar 

  69. Kanda M, et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut. 2013;62(7):1024–33.

    Article  CAS  PubMed  Google Scholar 

  70. Kanda M, et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol. 2013;11(6):719–30.e5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology & Hepatology, University of Rochester Medical Center, Rochester, NY, USA

    Shivangi Kothari, Vivek Kaul & Truptesh H. Kothari

Authors
  1. Shivangi Kothari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivek Kaul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Truptesh H. Kothari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shivangi Kothari .

Editor information

Editors and Affiliations

  1. Medical Director, Capital Health Medical Center Hopewell, Pennington, NJ, USA

    Cataldo Doria

  2. Capital Health Center for Digestive Health, Pennington, NJ, USA

    Jason N. Rogart

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Kothari, S., Kaul, V., Kothari, T.H. (2021). Reducing the Risk of and Screening for Pancreatic Cancer. In: Doria, C., Rogart, J.N. (eds) Hepato-Pancreato-Biliary Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-37482-2_35-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-37482-2_35-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-37482-2

  • Online ISBN: 978-3-030-37482-2

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation